Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells

BACKGROUND: Glioblastoma (GBM) is an aggressive brain tumor with universal recurrence and poor prognosis. The recurrence is largely driven by chemoradiation resistant cancer stem cells (CSCs). Epidermal growth factor receptor (EGFR) and its mutant EGFRvIII are amplified in ~ 60% and ~ 30% of GBM pat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Clin Cancer Res
Main Authors: Vengoji, Raghupathy, Macha, Muzafar A., Nimmakayala, Rama Krishna, Rachagani, Satyanarayana, Siddiqui, Jawed A., Mallya, Kavita, Gorantla, Santhi, Jain, Maneesh, Ponnusamy, Moorthy P., Batra, Surinder K., Shonka, Nicole
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6582495/
https://ncbi.nlm.nih.gov/pubmed/31215502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1264-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados